Home › Kanser sa Bato (Renal Cell Carcinoma) › Tennessee › Nashville
Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) sa Nashville, TN
Isang pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Nashville. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Nagre-recruitPhase 1
- Research Site, Nashville
- Research Site, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- Tennessee Oncology, Nashville
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Nagre-recruitPhase 1/2
- Vanderbilt University Medical Center ( Site 5004), Nashville
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Nagre-recruitPhase 1
- Sarah Cannon Research Institute (SCRI), Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #3, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
- Research Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Nagre-recruitObservasyonal na pag-aaral
- Vanderbilt University Medical Center, Nashville
Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
- Vanderbilt University Medical Center, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Nagre-recruitPhase 1/2
- Vanderbilt University Medical Center, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC- Elliston Place Plaza, Nashville
- at 11 pa
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Nagre-recruitPhase 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Nagre-recruitPhase 2
- Vanderbilt-Ingram Cancer Center, Nashville
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Nagre-recruitPhase 3
- Vanderbilt University/Ingram Cancer Center, Nashville
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Nagre-recruitPhase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Nagre-recruitPhase 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Vanderbilt University Medical Center, Nashville
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
- Xencor Investigative Site, Nashville
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Nagre-recruitPhase 1
- SCRI - Oncology Partners, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Nagre-recruit
- Vanderbilt-Ingram Cancer Center, Nashville
Pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) sa ibang lungsod
- Houston, TX35 pag-aaral
- New York City, NY27 pag-aaral
- Dallas, TX23 pag-aaral
- St. Louis, MO23 pag-aaral
- Los Angeles, CA20 pag-aaral
- Boston, MA16 pag-aaral
- Baldwin Park, CA16 pag-aaral
- Philadelphia, PA15 pag-aaral
- Pittsburgh, PA15 pag-aaral
- Queens, NY15 pag-aaral
- Cleveland, OH14 pag-aaral
- Jacksonville, FL14 pag-aaral
Iba pang pag-aaral sa Nashville
- Non-Small Cell Lung Cancer97 pag-aaral
- Kanser sa Suso81 pag-aaral
- Metastatic Cancer70 pag-aaral
- Colorectal Cancer69 pag-aaral
- Kanser (lahat ng uri)65 pag-aaral
- Kanser sa Ovary49 pag-aaral
- Kanser sa Prostate43 pag-aaral
- Kanser sa Baga40 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg39 pag-aaral
- Kanser sa Pancreas39 pag-aaral
- Kanser ng Endometrium38 pag-aaral
- Melanoma33 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.